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Abstract
Background: Cigarette smoking induces dopamine release in the striatum, and smoking- or nicotine-induced ventral striatal 
dopamine release is correlated with nicotine dependence. Smokers also exhibit lower dopamine D2/3 receptor availability 
in the dorsal striatum than nonsmokers. Negative correlations of striatal dopamine D2/3 receptor availability with smoking 
exposure and nicotine dependence, therefore, might be expected but have not been tested.
Methods: Twenty smokers had positron emission tomography scans with [18F]fallypride to measure dopamine D2/3 receptor 
availability in ventral and dorsal regions of the striatum and provided self-report measures of recent and lifetime smoking 
and of nicotine dependence.
Results: As reported before, lifetime smoking was correlated with nicotine dependence. New findings were that ventral 
striatal dopamine D2/3 receptor availability was negatively correlated with recent and lifetime smoking and also with 
nicotine dependence.
Conclusion: The results suggest an effect of smoking on ventral striatal D2/3 dopamine receptors that may contribute to 
nicotine dependence.
Keywords: nicotine dependence, dopamine, D2 receptors, positron emission tomography
Introduction
Cigarette smoking is a major contributor to premature death 
throughout the civilized world through its role in promoting 
disease, including cancer as well as cardiovascular, pulmo-
nary, and metabolic diseases (National Center for Chronic 
Disease, 2014). Although smoking cessation reverses many of 
the negative consequences of cigarette use (Thun et al., 2013), 
long-term abstinence from smoking is difficult to achieve and 
relapse rates are high even with treatment (Prochaska and 
Benowitz, 2016). Thus, new efficacious treatments are needed, 
and enhanced knowledge of the mechanisms that promote 
nicotine dependence may facilitate their design.
Like other addictive drugs, nicotine administration acutely 
increases synaptic dopamine. In human studies, positron emis-
sion tomography (PET) has revealed decreases in striatal dopa-
mine D2-type (i.e., D2 and D3, D2/3) receptor availability (binding 
potential, BPnd), reflecting dopamine release in the ventral 
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striatum, following cigarette smoking (Brody et al., 2004; Le Foll 
et al., 2014). The magnitude of dopamine release in the ventral 
striatum has been related to relief of cigarette craving and with-
drawal symptoms (Brody et al., 2004; Le Foll et al., 2014). These 
findings suggest a role of ventral striatal dopaminergic signaling 
in nicotine dependence.
In male smokers, D2/3 BPnd in the putamen was lower than in 
nonsmokers both immediately after smoking and after 24 hours 
of abstinence (Fehr et al., 2008). The difference in baseline BPnd in 
males was replicated in a study that showed a similar difference 
in the caudate nucleus but no smoking-related group difference 
in women (Brown et  al., 2012). Nicotine dependence has been 
correlated positively with lifetime cigarette smoking (Lindberg 
et al., 2015) and negatively with D2/3 BPnd in the ventral striatum 
and the anterior putamen (Montgomery et  al., 2007), but asso-
ciations of D2/3 BPnd with recent or lifetime cigarette smoking 
have not been reported. The goal of this study, therefore, was to 
test for associations of dopamine D2/3 BPnd in the ventral and 
dorsal striatum with recent and lifetime cigarette use; negative 
associations were expected. A secondary goal was to determine 
whether striatal D2/3 BPnd plays a role in the observed relation-
ship between lifetime smoking and nicotine dependence.
Methods
Participants
All procedures were approved by the University of California 
Los Angeles Office for the Protection of Research Subjects. 
Twenty participants, 18 to 55  years old, who endorsed daily 
smoking, were recruited using Internet and local newspaper 
advertisements. After receiving a complete explanation of the 
study procedures, the participants provided written, informed 
consent and were screened for eligibility, and carbon mon-
oxide in expired air was measured to verify recent smoking. 
Exclusion criteria were use of any psychotropic medications; 
presence of central nervous system, cardiovascular, pulmo-
nary, or systemic disease; human immunodeficiency virus-
seropositive status; hepatic disease; pregnancy; lack of English 
fluency; magnetic resonance imaging (MRI) contraindica-
tions; or current DSM-IV Axis-I diagnoses except for nicotine 
dependence, measured using the Structured Clinical Interview 
for DSM-IV.
Demographics and Smoking-Related Ratings
Data collected included age, sex, and recent as well as lifetime 
smoking history and use of other substances (e.g., alcohol and 
marijuana) in the month before enrollment. Lifetime smoking 
was measured in pack-years (i.e., packs per day × years of smok-
ing). In cases where smoking cessation had exceeded 1 year, the 
time was subtracted from the years of smoking. The Fagerström 
Test for Nicotine Dependence (FTND) was used to measure 
dependence.
PET/MRI Scanning and Data Processing
Participants were abstinent from smoking for >2 h before each PET 
scan, which was performed with [18F]fallypride, a radiotracer for 
dopamine D2/3 receptors. PET data were acquired using a Siemens 
ECAT EXACT HR+ scanner, which has an in-plane resolution full-
width at half-maximum of 4.6 mm, axial resolution full-width at 
half-maximum of 3.5 mm, and an axial field of view of 15.52 cm in 
the 3D mode. Participants were placed in the supine position with 
the head secured with plastic tape to avoid movement during 
the scan. After a transmission scan using a rotating 68Ga⁄68Ge rod 
source, emission data were collected for 80 minutes after a bolus 
injection of 185 MBq (±10%; range of 175–203 MBq) [18F]fallypride, 
which had a specific activity of >1 Ci/µmol; 3.19–21.6 Ci/µmol). 
Participants were then removed from the scanner for a 20-minute 
break. They then returned to the scanner and were repositioned, 
and emission data were collected for 80 minutes.
Reconstructed PET data were combined into 16 frames, 
each containing data averaged over 10 minutes. FSL MCFLIRT 
(FMRIB Centre, Department of Clinical Neurology, University 
of Oxford, Oxford, UK) was used to correct for head motion. 
Structural MRI scans of the brain were acquired for co-regis-
tration with PET images and definition of volumes-of-interest 
(VOIs). A  T1-weighted scan was acquired using a whole-brain 
magnetization-prepared rapid acquisition with gradient echo 
(MPRAGE) (TR  =  1900 ms, TE  =  4.38 ms, flip angle  =  15, field of 
view = 256 × 256 × 160, 160 slices, thickness = 1 mm). PET data were 
co-registered to the respective MPRAGE images using FSL FLIRT.
A VOI encompassing the whole striatum was first anatomically 
defined using FSL FIRST on the MPRAGE image of each participant, 
then a VOI for the ventral striatum was separated according to 
anatomical landmarks (Mawlawi et al., 2001). The rest of the stria-
tum was defined as dorsal striatum. In addition, for exploratory 
analyses, VOIs representing extrastriatal regions (i.e., thalamus, 
globus pallidus, amygdala, and hippocampus) were generated 
using FSL FIRST. The cerebellum, which has a very low concen-
tration of D2/3 dopamine receptors, was used as a reference 
region. Cerebellar VOIs, manually drawn on hemispheres while 
avoiding the vermis in standard space (MNI152 template), were 
transformed into native space with FSL FNIRT. Time-activity data 
within VOIs were extracted from motion-corrected, co-registered 
PET images and imported into PMOD Kinetic Modeling (PMOD 
Technologies Ltd., Zurich, Switzerland). A volume-weighted aver-
age of k2´, the rate constant for the transfer of the radiotracer 
from the reference-region tissue compartment to the plasma, 
was estimated from time-activity data for regions of high receptor 
density (caudate and putamen VOIs as determined by FSL FIRST) 
using the simplified reference tissue model (Lammertsma and 
Hume, 1996). The time-activity data for VOIs were refit with the 
simplified reference tissue model 2 (Wu and Carson, 2002) using 
PMOD Kinetic Modeling, fixing the computed k2´value. Receptor 
availability was then calculated as BPnd = R1*k2´/k2a – 1, where 
R1 = K1/K1´ is the ratio of tracer-delivery parameters from plasma 
to tissues in the target region and reference region, and k2a is the 
Significance Statement
This study utilized positron emission tomography to measure striatal dopamine D2/3 receptor availability in cigarette 
smokers. D2/3 receptor availability in ventral striatum was negatively correlated with measures of recent and lifetime 
smoking and of nicotine dependence. Additionally, a negative relationship of lifetime smoking with nicotine dependence 
was not significant when controlling for D2/3 receptor availability in ventral striatum. These results suggest a potential 
role of smoking-induced D2/3-receptor down regulation in ventral striatum on nicotine dependence.
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single-compartment rate constant for transfer from the target-
region tissue compartment to plasma.
Statistical Analyses
Pearson correlation analysis was used to evaluate relationships 
between cigarettes/day, pack-years, and FTND. Relationships of 
BPnd with cigarettes/day and FTND were evaluated using par-
tial correlation analysis controlling for age and sex. Statistical 
analyses involving pack-years were performed controlling solely 
for sex, because age is highly correlated with pack-years. To 
test potential effects of aging and lifetime smoking on striatal 
volume, Pearson correlation analysis was conducted to evalu-
ate relationships of striatum volume with age and pack-years. 
Multiple regression analysis was conducted to assess whether 
ventral striatal BPnd contributes to the relationship of lifetime 
smoking with nicotine dependence, with FTND score as the 
dependent variable, and sex, pack-years, and ventral striatal 
BPnd as independent variables. All of the statistical analyses 
were conducted using SPSS IBM 19 (IBM, Armonk, NY). The cri-
terion for statistical significance was P < .05 (2-tailed). P values 
for correlation analysis involving striatal BPnd were corrected 
for 2 comparisons (i.e., ventral and dorsal striatum), whereas P 
values for the extrastriatal regions were not corrected, because 
analyses of data from these regions was exploratory.
Results
Participant Characteristics
There were 20 (11 males and 9 females) participants, 37.8 ± 7.50 
(mean ± SD) years of age, in the study. Although all endorsed 
daily smoking, each met the criterion of a CO level >8 ppm in 
expired air at screening, and mean expired CO at screening was 
17.4 ± 7.51 ppm; only 12 participants met DSM-IV criteria for cur-
rent nicotine dependence. On average, the participants started 
smoking regularly at 19.5 ± 9.14 years of age, with recent daily con-
sumption of 14.1 ± 5.73 cigarettes and a lifetime smoking history of 
13.7 ± 6.93 pack-years. The average FTND score was 3.7 ± 1.87, rang-
ing from 0 to 7. Twelve participants reported using alcohol in the 
month before study, with use on 4.2 ± 2.73 days in the month. Two 
participants reported recent, light marijuana use, each indicating 
use on 1 day during the month before enrolling in the study.
Associations of Current and Lifetime Smoking with 
Nicotine Dependence and D2/3 BPnd and of Nicotine 
Dependence with BPnd
Lifetime smoking, measured in pack-years, was correlated with 
FTND score (r = 0.471, P = .04 [controlled for sex]), whereas recent 
use, indicated by cigarettes/day, was not (r = 0.301, P =  .20 [con-
trolled for sex]). However, both measures of cigarette use were 
negatively correlated with BPnd in the ventral striatum (pack-
years: r  =  -0.640, P  =  .006 [controlled for sex]); cigarettes/day: 
r  =  -0.587, P  =  .02 [controlled for age and sex]). BPnd in dorsal 
striatum was not significantly correlated with either index (pack-
years: r = -0.350, P = .28; cigarettes/day: r = -0.330, P = .36 [controlled 
for age and sex]). BPnd in both striatal regions was significantly 
negatively correlated (controlled for age and sex) with FTND score 
(ventral: r = -0.610, P = .01; dorsal: r = -0.552, P = .04) (Figure 1).
Exploratory analyses showed associations of BPnd in other 
subcortical regions with current and lifetime smoking and 
nicotine-dependence measures. Effects had the same sign as 
those involving striatal regions, although significance did not 
survive multiple-comparisons correction: thalamus (pack-
years: r = -0.436, P = .06; cigarettes/day: r = -0.440, P = .07; FTND: 
r = -0.476, P = .05), globus pallidus (pack-years: r = -0.250, P = .30; 
cigarettes/day: r = -0.348, P = .16; FTND: r = -0.479, P = .04), amyg-
dala (pack-years: r  =  -0.501, P  =  .03; cigarettes/day: r  =  -0.542, 
P  =  .02; FTND: r  =  -0.521, P  =  .03), and hippocampus (pack-
years: r = -0.343, P = .15; cigarettes/day: r = -0.476, P = .05; FTND: 
r = -0.497, P = .04) (Ps uncorrected for multiple comparisons).
Associations of Age and Lifetime Smoking with 
Striatum Volume
Whole striatal volume was not correlated with age (r = -0.062, 
P  =  .80) or pack-years (r  =  0.328, P  =  .16). These results were 
minimally affected by controlling for whole-brain volume (age: 
r = -0.021, P = .93; pack-years: r = 0.335, P = .15).
Role of Ventral Striatal BPnd in the Association of 
Lifetime Smoking with Nicotine Dependence
Regression analyses demonstrated a significant effect of pack-
years on FTND score (B = 0.13, SE = 0.06, P = .04), of pack-years 
on BPnd (B  =  -0.27, SE  =  0.08, P  =  .003), and of BPnd on FTND 
(B = -0.43, SE = 0.11, P = .002). The association of pack-years with 
FTND did not remain significant after controlling for ventral 
striatal BPnd (B = 0.02, SE = 0.06, P = .78), whereas ventral striatal 
Figure  1. Associations of striatal D2/3 binding potential (BPnd) with cigarette 
use and nicotine dependence. Scatter plots are shown for associations with 
correlation coefficients. *P < .05, ** P < .01. FTND, Fagerström Test for Nicotine 
Dependence.
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BPnd remained a significant predictor (B  =  -0.40, SE  =  0.15, 
P = .02) after controlling for pack-years (Figure 2).
Discussion
This study found negative associations of ventral striatal dopa-
mine D2/3 BPnd with lifetime and recent cigarette use and with 
nicotine dependence. In addition, multiple regression analysis, 
demonstrating that correlation of lifetime smoking with nicotine 
dependence was no longer significant when controlling for ven-
tral striatal BPnd, suggested that low ventral striatal D2/3 recep-
tor signaling may contribute to nicotine dependence. Therefore, 
enhancing D2/3 receptor availability in ventral striatum may rep-
resent a therapeutic approach to reduce nicotine dependence.
The positive association of pack-years with FTND score 
(Lindberg et  al., 2015) is consistent with a previous report and 
with the fact that the transition from daily smoking to nicotine 
dependence occurs years after the initiation of daily smoking 
(Breslau et  al., 2001). In rats, chronic nicotine administration 
reduces D2 receptor density in the basal ganglia, preferentially 
in ventral striatum, and counteracts lesion-induced upregulation 
of striatal D2 receptor density (Janson et al., 1992). The observed 
negative association of lifetime smoking with D2/3 BPnd in 
human subjects is in line with these observations and suggests 
that cigarette smoking causes D2/3-receptor downregulation in 
ventral striatum, although the possibility that low D2/3 BPnd in 
ventral striatum promotes smoking behavior cannot be excluded.
A negative association of striatal D2/3 BPnd with nicotine 
dependence was reported before (Montgomery et al., 2007) and 
may reflect inhibitory control problems. In this regard, striatal 
D2/3 BPnd has been correlated positively with capacity for 
response inhibition in healthy subjects (Ghahremani et al., 2012) 
and negatively with impulsivity in methamphetamine users 
(London, 2016). Notably, impulsivity has been linked to cigarette 
craving and relapse to tobacco use (Potvin et al., 2015). The over-
all findings of this study are generally consistent with a model 
of addiction proposed by Trifilieff and Martinez (2014), whereby 
reduced signaling through D2/3 receptors accompanies impul-
sivity and both conditions can be exacerbated by drug exposure. 
It was proposed that increasing D2/3 receptor signaling is a 
potential treatment for addiction, which is suggested as well by 
this study.
One approach to enhance striatal D2/3 BPnd is through exer-
cise training, as has been suggested for patients with stimulant 
use disorder (Robertson et al., 2015). Exercise was proposed as a 
smoking-cessation aid long ago, and there are some reports of 
benefits from exercise in reducing tobacco consumption, albeit 
with limited evidence of long-term benefit (Ussher et al., 2014). 
In addition, subchronic administration of varenicline, which has 
efficacy in promoting smoking cessation, produces striatal D2/3 
receptor upregulation in rats (Crunelle et  al., 2009) as well as 
dopamine release in striatum, demonstrated by [11C]-(+)-PHNO 
and PET in smokers (Di Ciano et al., 2015).
This study has limitations. Because it was a cross-sectional 
study, a causal relationship between smoking and BPnd can-
not be claimed. Moreover, the fact that [18F]fallypride binds to 
D2 and D3 receptors, with up to 20% of the striatal signal asso-
ciated with D3 receptors (Mukherjee et  al., 2015), precludes 
definitive statements regarding either receptor subtype. 
Notably, D3 receptors are highly expressed in ventral stria-
tum (Diaz et al., 2000). Although participants were abstinent 
from smoking ≥2 h before PET scans, the time of last smoking 
was not recorded, but it seems unlikely that recent smoking 
affected BPnd measurements in this study, because D2/3 BPnd 
measured with [18F]fallypride was unchanged immediately 
after smoking compared with after overnight abstinence (Fehr 
et al., 2008). Lack of effect on D2/3 BPnd measured with [18F]
fallypride after dopamine depletion with α-methyltyrosine 
BPnd is further evidence that this measure is minimally 
affected by differences in tonic intrasynaptic dopamine levels 
(Cropley et al., 2008). In spite of those limitations, this study 
demonstrates robust negative associations of ventral striatal 
dopamine D2/3 BPnd with lifetime smoking and suggests 
a potential role of ventral striatal D2/3 receptors in nicotine 
dependence.
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